RALEIGH, N.C., June 14, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced an extensive presence at the DIA 2017 53rd Annual Meeting being held June 18-22 in Chicago, Illinois. INC Research thought leaders will be participating in educational sessions covering new regulations for medical devices, accelerating research and development for rare diseases, innovative approaches to enrolling hard-to-find subjects, improving CRO and sponsor relations, and more. In addition, INC executives will be at Booth #2015 to discuss a range of topics impacting clinical development, including the adoption of the new ICH E6 (R2) monitoring protocol.
Preparing for ICH E6 R2 Implementation
With the new ICH E6 R2 regulation going into effect in Europe this past week, INC Research’s focus at DIA this year will be on ICH E6 R2 preparedness. Company thought leaders will offer key considerations for assessing an organization’s readiness and suggest ways to maximize the opportunities provided by advances in technology and in risk-based monitoring approaches, while reducing the challenges that pose a threat to a successful implementation. Visitors to the INC booth will be invited to complete a five-question ICH preparedness survey. For every person who completes the survey, INC will make a $5 donation to the Make-A-Wish Foundation.
“Every year, DIA provides an opportunity for the best and brightest in clinical research to exchange ideas that aim to drive positive changes in enhancing the drug development process,” said INC Research CEO Alistair Macdonald. “This year at DIA, our goal is to bring some novel approaches to the table that challenge traditional thinking. At INC Research, we believe collaboration is key to the advancement of drug development. That’s why we remain steadfast in our commitment to forging strong relationships with sites, sponsors and the clinical research community as a whole, so that we can develop better strategies for reducing costs and development times for life-saving medicines.”
Contributing to the discussion at DIA
INC Research thought leaders will contribute to discussions at DIA on the following topics:
- Elaine Taylor, Executive Director, Regulatory Consulting
#21: Successful Drug Development: Best Practices for Drug Development Planning, Agency Interactions, and Regulatory Document Writing
Speaker Session: Sunday, June 18, 8:30 a.m.
- Dr. Galina Bernstein, Director of Pharmacometrics, Early Phase
#124: Exploration of PK/PD in NDA Enabling of Early Proof of Concept Studies
Speaker Session: Monday, June 19 at 11:00 a.m.
- Keith Ruark, Executive Director, Strategy Consulting
#121: Effective Life Cycle Management
Speaker Session: Monday, June 19 at 11:00 a.m.
- Dr. Nicholas Kenny, Executive Vice President, Oncology and Hematology
#228: Master Protocols: New Approaches to Enrolling Hard-to-Find Subjects and Expediting Drug Development
Speaker Session: Tuesday, June 20 at 10:30 a.m.
- David Burnham, Senior Vice President, Strategic Alliances
#232: Engage and Exchange - Health CRO/Sponsor Relations: “Sole” Mate or Flavor of the Month
Speaker Session: Tuesday, June 20 at 10:45 a.m.
- Angela Stokes, Senior Director, Global Regulatory Consulting
#252: What’s New in Devices: European Medical Device Regulations and MDUFA IV
Speaker Session: Tuesday, June 20 at 2:00 p.m.
- Andrew Townshend, Senior Vice President, Alliance Development
#323: Effective Collaborations: Navigating the Grey Space
Forum: Wednesday, June 21 at 10:30 a.m.
- Dr. Judith Ng-Cashin, Chief Scientific Officer
#352: Collaborative Efforts to Accelerate Rare Disease Research and Development
Forum: Wednesday, June 21 at 2:00 p.m.
- Jill Collins, Executive Director, Global Operations Management, Innovation
#364: Risk-Based Monitoring: Convergence of Technology, Processes, and People: Panel Discussions
Forum: Wednesday, June 21 at 4:00 p.m.
Recognizing clinical research sites
INC Research is hosting its fourth annual Site Appreciation Reception for site representatives on Monday, June 19, from 6:30 to 9:30 p.m. The event, which recognizes the importance of clinical research sites and thanks them for their ongoing contributions to the drug development process, will be hosted by Clare Grace, PhD, Vice President, Site and Patient Access, and Tracey Gashi, PhD, Executive Director, Site and Patient Access. The guest speaker will be Christine Pierre, President of the Society for Clinical Research Sites (SCRS). INC Research will meet with clinical research site professionals to discuss ways to work together more effectively to enhance the clinical development process for the benefit of patients, as well as provide insight into what the new ICH E6 R2 GCP addendum means for sites. For more information on this event, interested sites should visit booth #2015. To view highlights from last year’s DIA site event, click here.
Connect with us
For more information or to schedule a meeting at DIA, visit the INC Research site, stop by Booth #2015 at the conference or connect with us on social media - Twitter, LinkedIn and Facebook.
About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was ranked “Top CRO to Work With” among the top 10 global CROs in the 2017 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.